Thus, we conclude that the ERβ agonist treatment increased MLH1 expression, which enhanced the sensitivity of CRC tumor to 5-FU and subsequently inhibited tumor proliferation in vivo. This evidence concerns the gene MLH1 and colorectal carcinoma.